ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Fractional Flow Reserve–Guided PCI for Stable Coronary Artery Disease

Friday, September 5, 2014

Submitted by

Mark Ferguson

Source

Source Name: New England Journal of Medicine

Source URL: http://www.nejm.org/doi/full/10.1056/NEJMoa1408758?query=TOC

Author(s)

Bernard De Bruyne, William F. Fearon, Nico H.J. Pijls, Emanuele Barbato, Pim Tonino, Zsolt Piroth, Nikola Jagic, Sven Mobius-Winckler, Gilles Riouffol, Nils Witt, Petr Kala, Philip MacCarthy, Thomas Engström, Keith Oldroyd, Kreton Mavromatis, Ganesh Manoharan, Peter Verlee, Ole Frobert, Nick Curzen, Jane B. Johnson, Andreas Limacher, Eveline Nüesch, and Peter Jüni for the FAME 2 Trial Investigators

This controlled randomized trial examined the benefits of targeted PCI vs medical therapy alone for patients with stable CAD and stenosis who were found to have zones of fractional flow reserve of less than 0.8 at angiography. Patients without regions of FFR <0.8 were entered into a registry. The composite outcome was death, nonfatal MI, or urgent revascularization within 2 years. The PCI group had a lower incidence of the composite outcome, 8.1% vs 19.5%, driven by their lower rate of urgent revascularization. The registry group had a similar rate of the composite outcome as did the PCI group.